Danish biopharmaceutical company NeuroSearch has filed an application in Europe to begin Phase III clinical studies of drug candidate ACR16 for the treatment of Huntington’s disease. The work will involve centres in several countries, including UK, Germany, Austria, France, Belgium, Portugal and Spain. The news was reported on NeuroSearch's website.
Flemming Pedersen, CEO of NeuroSearch, comments in a press release: “The filing of the European Phase III application on ACR16 in Huntington’s disease is a major achievement for our company. We have reached this milestone timely in accordance with plans, and we are now one important step closer to having our first product on the market.”
ACR16 is one of a novel class of drugs called dopaminergic stabilisers, which can stabilize behavioural and motor disturbances caused by neurological and psychiatric disorders, without compromising normal thought processes or motor functions.
Huntington’s disease is a rare, inherited neurological disorder first described by the New York physician George Huntington in 1872. It is caused by a faulty gene which leads to progressive degeneration of nerve cells in the brain, resulting in a wide and distressing range of symptoms. The prevalence of Huntington’s disease is 5 to 8 per 100,000, varying geographically.
NeuroSearch develops novel drugs based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial part of the company’s activities are partner financed through a broad alliance with GlaxoSmithkline (GSK) and collaborations with Abbott and Astellas. NeuroSearch is listed on the OMX Nordic Exchange.